8-K: Bio-Techne Reports Q1 FY26 Results, Declares Dividend

Bio-Techne Corporation announced its first quarter fiscal 2026 financial results, reporting a 1% revenue decrease and flat adjusted EPS, alongside the declaration of a $0.08 per share cash dividend.

Summary

• Reported and organic revenue for the first quarter of fiscal year 2026 decreased 1% to $286.6 million.
• GAAP earnings per share (EPS) was $0.24, an increase from $0.21 for the first quarter of fiscal year 2025.
• Adjusted EPS remained flat at $0.42 compared to $0.42 for the first quarter of fiscal year 2025.
• The company completed the divestiture of its Exosome Diagnostics business, including the ExoDx Prostate test (EPI), to emphasize investment and commercial priorities on non-CLIA based product lines.
• Ongoing productivity and cost containment initiatives led to a 29.9% adjusted operating margin, an increase of 90 basis points compared to the prior year period.
• Shareholders voted to set the number of directors at nine, and all nine director nominees were elected.
• Shareholders adopted a non-binding resolution approving the compensation of the company's named executive officers.
• Shareholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026.
• A cash dividend of $0.08 per share was declared, payable on November 28, 2025, to shareholders of record on November 17, 2025.

Sentiment

Score: 6

Explanation: While revenue decreased and adjusted EPS was flat, the company demonstrated strong operational execution by expanding adjusted operating margin through productivity and divestiture. Strategic focus on growth pillars and positive developments for Cell Therapy customers (Fast Track) are encouraging, though short-term order timing headwinds exist.

Positives

• GAAP EPS increased to $0.24 from $0.21 in the prior year period.
• Adjusted operating margin improved by 90 basis points to 29.9% due to productivity initiatives, foreign exchange, and the Exosome Diagnostics divestiture.
• GAAP operating income increased 19% to $47.7 million, compared to $40.0 million in the prior year.
• GAAP operating margin improved to 16.6% from 13.8%, favorably impacted by a reduction in restructuring charges.
• Observed encouraging signs of stabilization in the US academic end market and continued strength from large pharmaceutical customers.
• ProteinSimple's analytical solutions extended its growth momentum.
• Spatial Biology stabilized and showed early signs of accelerating growth going forward.
• Several largest Cell Therapy customers received Fast Track Designation by the FDA, enabling shortened clinical development and approval timelines.
• The Diagnostics and Spatial Biology segment's operating margin increased to 11.2% from 5.1% due to volume leverage and the Exosome Diagnostics divestiture.
• A cash dividend of $0.08 per share was declared.

Negatives

• Reported and organic revenue decreased 1% to $286.6 million.
• Adjusted EPS remained flat at $0.42.
• Funding headwinds persisted for emerging biotech companies.
• Advancements in Cell Therapy, specifically Fast Track Designation for customers, resulted in shortand intermediate-term order timing headwinds for the GMP proteins business.
• The Protein Sciences segment's net sales decreased 1% to $202.2 million, with organic revenue decreasing 3%.
• The Protein Sciences segment's operating margin decreased to 38.4% from 39.4% primarily due to a reduction in volume leverage.
• The Diagnostics and Spatial Biology segment's net sales decreased 4% to $79.5 million.

Risks

• The effect of new branding and marketing initiatives.
• The integration of new businesses and leadership.
• The introduction and acceptance of new products.
• The funding and focus of the types of research by customers.
• The impact of the growing number of producers of biotechnology research products and related price competition.
• General economic conditions.
• The impact of currency exchange rate fluctuations.
• The costs and results of research and product development efforts of the company and of companies in which the company has invested or with which it has formed strategic relationships.
• Shortand intermediate-term order timing headwinds for the GMP proteins business due to Cell Therapy advancements.
• Reduction in volume leverage impacting the Protein Sciences segment's operating margin.
• Funding headwinds persisting for emerging biotech companies.

Future Outlook

The company expects to deliver long-term value for all stakeholders, leveraging its differentiated portfolio, world-class team, sharpened strategic focus, innovation capabilities, and sector-leading financial profile. It anticipates continued strength from large pharmaceutical customers and stabilization in the US academic end market, with Spatial Biology showing early signs of accelerating growth. However, shortand intermediate-term order timing headwinds are expected for the GMP proteins business due to Cell Therapy advancements.

Management Comments

• Kim Kelderman, President and CEO, stated that the Bio-Techne team once again executed with focus and agility in a dynamic operating environment, observing encouraging signs of stabilization in the US academic end market and continued strength from large pharmaceutical customers, while funding headwinds persisted for emerging biotech companies.
• Kelderman highlighted that among the company's growth pillars, ProteinSimple's analytical solutions extended its growth momentum and Spatial Biology stabilized while showing early signs of accelerating growth going forward.
• Kelderman expressed excitement that several largest Cell Therapy customers received Fast Track Designation by the FDA, enabling shortened clinical development and approval timelines, but noted that these advancements have resulted in shortand intermediate-term order timing headwinds for the GMP proteins business.
• Kelderman affirmed that with its world-class team, sharpened strategic focus, innovation capabilities, and sector-leading financial profile, Bio-Techne remains well positioned to deliver long-term value for all stakeholders.

Industry Context

The life sciences industry is experiencing a dynamic operating environment, with varying trends across different customer segments. While large pharmaceutical customers show continued strength and the US academic market stabilizes, emerging biotech companies face persistent funding headwinds. The company's focus on non-CLIA based product lines and growth pillars like ProteinSimple and Spatial Biology aligns with broader trends towards advanced research tools and diagnostics. The Fast Track Designation for Cell Therapy customers indicates a rapidly evolving and high-potential area, though it presents short-term order timing challenges for suppliers like Bio-Techne.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders will receive a $0.08 per share cash dividend. Their vote on directors, executive compensation, and auditor ratification impacts corporate governance and oversight. The flat adjusted EPS and revenue decrease could impact short-term share price, while strategic divestiture and margin improvements aim for long-term value.
• Employees may be affected by productivity and cost containment initiatives, along with restructuring charges, which could imply efficiency drives or workforce adjustments.
• Customers in the US academic end market show stabilization, and large pharmaceutical customers show continued strength. Emerging biotech customers face funding headwinds. Cell Therapy customers benefit from Fast Track Designation, but this creates short-term order timing headwinds for the company's GMP proteins business.
• Creditors benefit from a decrease in long-term debt obligations from $346,000 to $300,000, indicating debt reduction.

Next Steps

• Bio-Techne will host an earnings conference call on November 5, 2025, at 8:00 a.m. CST.
• Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Key Dates

Recommendation

The company reported a 1% decrease in revenue and flat adjusted EPS, indicating a challenging operating environment. However, strong execution on productivity and cost containment led to a 90 basis point increase in adjusted operating margin to 29.9%, and GAAP EPS improved. The strategic divestiture of the Exosome Diagnostics business sharpens focus on core growth pillars. While there are positive signs in specific segments like ProteinSimple and Spatial Biology, and Fast Track Designation for Cell Therapy customers is a long-term positive, short-term order timing headwinds for GMP proteins and funding challenges for emerging biotech create uncertainty. Given the mixed performance with strategic positives balanced by operational headwinds, a 'hold' recommendation is appropriate as investors await clearer signs of revenue re-acceleration and the full impact of strategic shifts.

Keywords

Bio-Techne, TECH, financial results, Q1 2026, earnings, revenue, EPS, dividend, SEC filing, 8-K, life sciences, biotechnology, Protein Sciences, Diagnostics, Spatial Biology, corporate governance, shareholder vote, divestiture, Exosome Diagnostics, GMP proteins, Fast Track Designation, operating margin